| VRTX |
Report |
Total revenue |
IN-LINE |
pred ~$3.240B vs. cons $3.221B |
MEDIUM |
| VRTX |
Report |
ALYFTREK revenue |
BEAT |
pred ~$530M vs. cons $521M |
MEDIUM |
| VRTX |
Report |
JOURNAVX revenue |
BEAT |
pred ~$52M vs. cons $49.1M |
MEDIUM |
| VRTX |
Guide |
FY26 total revenue |
UNCHANGED |
guide $12.95B-$13.10B vs. cons $13.053B |
MEDIUM |
| VRTX |
Guide |
FY26 non-CF revenue |
UNCHANGED |
guide $500M+ vs. cons UNVERIFIED |
LOW |
| VRTX |
Guide |
FY26 JOURNAVX commercial outlook |
UNCHANGED |
reaffirm >3x revenue growth vs. cons $239.8M |
LOW |
| VRTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| VRTX |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained guide leaves no estimate catalyst |
LOW |